Alkermes Plc (NASDAQ:ALKS) Director Richard F. Pops sold 50,000 shares of the business’s stock in a transaction dated Wednesday, May 17th. The shares were sold at an average price of $58.19, for a total value of $2,909,500.00. Following the completion of the sale, the director now directly owns 680,406 shares of the company’s stock, valued at $39,592,825.14. The sale was disclosed in a legal filing with the SEC, which is available through this link.
Shares of Alkermes Plc (NASDAQ:ALKS) traded down 0.03% during mid-day trading on Friday, reaching $57.91. The company’s stock had a trading volume of 728,646 shares. Alkermes Plc has a 12 month low of $39.36 and a 12 month high of $62.50. The company has a 50-day moving average of $57.84 and a 200-day moving average of $56.84. The company’s market cap is $8.87 billion.
Alkermes Plc (NASDAQ:ALKS) last released its earnings results on Thursday, April 27th. The company reported ($0.31) earnings per share (EPS) for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.24) by $0.07. Alkermes Plc had a negative net margin of 36.92% and a negative return on equity of 12.75%. The business had revenue of $191.80 million for the quarter, compared to analysts’ expectations of $195.79 million. During the same quarter in the previous year, the business posted ($0.16) earnings per share. Alkermes Plc’s revenue for the quarter was up 22.3% on a year-over-year basis. Equities research analysts forecast that Alkermes Plc will post ($0.04) earnings per share for the current fiscal year.
ILLEGAL ACTIVITY NOTICE: “Alkermes Plc (ALKS) Director Richard F. Pops Sells 50,000 Shares” was originally reported by Mideast Time and is the property of of Mideast Time. If you are viewing this article on another website, it was copied illegally and republished in violation of U.S. & international trademark & copyright laws. The legal version of this article can be accessed at https://www.mideasttime.com/alkermes-plc-alks-director-richard-f-pops-sells-50000-shares/1708159.html.
Institutional investors have recently added to or reduced their stakes in the stock. Massey Quick & Co. LLC acquired a new position in Alkermes Plc during the fourth quarter valued at about $111,000. Greenwood Capital Associates LLC acquired a new position in Alkermes Plc during the fourth quarter valued at about $202,000. Mn Services Vermogensbeheer B.V. raised its position in Alkermes Plc by 5.9% in the first quarter. Mn Services Vermogensbeheer B.V. now owns 4,053 shares of the company’s stock valued at $222,000 after buying an additional 224 shares during the last quarter. Nomura Holdings Inc. acquired a new position in Alkermes Plc during the first quarter valued at about $266,000. Finally, Decatur Capital Management Inc. acquired a new position in Alkermes Plc during the first quarter valued at about $267,000. Hedge funds and other institutional investors own 95.52% of the company’s stock.
A number of brokerages recently commented on ALKS. Credit Suisse Group AG set a $70.00 target price on Alkermes Plc and gave the company a “buy” rating in a research report on Friday. Cowen and Company reaffirmed a “buy” rating on shares of Alkermes Plc in a research report on Friday, April 28th. JPMorgan Chase & Co. set a $78.00 price objective on Alkermes Plc and gave the stock a “buy” rating in a report on Thursday, April 27th. Morgan Stanley reissued an “equal weight” rating and set a $62.00 price objective on shares of Alkermes Plc in a report on Monday, April 24th. Finally, Jefferies Group LLC reissued a “buy” rating and set a $70.00 price objective on shares of Alkermes Plc in a report on Monday, April 3rd. Four analysts have rated the stock with a hold rating and seven have issued a buy rating to the company’s stock. The stock has a consensus rating of “Buy” and a consensus price target of $63.55.
About Alkermes Plc
Alkermes plc is a biopharmaceutical company. The Company is engaged in the researching, developing and commercializing pharmaceutical products that are designed to address medical needs of patients in therapeutic areas. The Company has a portfolio of marketed drug products and a clinical pipeline of products that address central nervous system (CNS) disorders, such as schizophrenia, depression, addiction and multiple sclerosis (MS).
Receive News & Ratings for Alkermes Plc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Alkermes Plc and related companies with MarketBeat.com's FREE daily email newsletter.